Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05226871 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

StatusActive, Not Recruiting
PhasePhase 2
SponsorPfizer
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 years later Dec 31, 2026 → Dec 31, 2029
See other at-risk trials from Pfizer

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Dec 31, 2026 to Dec 31, 2029
    • Study sites revised (23)
    v15
  2. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 22 to 23
    v14
  3. Study sites: 17 to 22v13
  4. Study sites: 9 to 17v12
  5. Primary and study completion dates: Apr 19, 2026 to Dec 31, 2026
    • Study sites: 8 to 9
    v11
Show 9 earlier versionsHide 9 earlier versions
  1. Site details revised at 1 of 8 sitesv10
  2. Study sites: 7 to 8v9
  3. Site details revised at 3 of 7 sitesv8
  4. Study sites: 6 to 7v7
  5. Study sites: 5 to 6v6
  6. Study sites: 4 to 5v5
  7. Study title revisedv4
  8. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 4
    v3
  9. Start date: May 5, 2022 to Jul 7, 2022
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pfizer
436 trials monitored
See 32 trials at risk
Breast Cancer
5,418 trials monitored
See 296 trials at risk
Head & Neck Cancer
2,605 trials monitored
See 150 trials at risk
The purpose of this clinical trial is to provide study medicine(s) and learn about their safety. This study is seeking participants who: * Have benefited from ongoing study treatment as determined by the study doctor in a Pfizer-sponsored palbociclib Parent Study * Must agree to follow the reproductive criteria * Are willing and able to comply with all scheduled visits, treatment plans, and other study procedures * Can give signed informed consent documents Participants in this study will continue to receive treatment as they were in the parent study. The time by which participants will take part in this study is retrospective (after completed parent study). We will examine the experiences of people receiving the study medicine(s). This will help us determine if the study medicine(s) are safe. During this time, the participants will be monitored for the safety of the study medicine(s).
Trial Details
NCT Number NCT05226871
Lead Sponsor Pfizer
Conditions
(from sponsor)		 Breast Cancer, Head and Neck Cancer
Related terms Breast Neoplasms, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov